Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

Conditions:   Head Neck;   Squamous Cell Carcinoma of Head and Neck Interventions:   Drug: Pembrolizumab;   Drug: Magrolimab;   Drug: cetuximab;   Drug: Docetaxel Sponsors:   M.D. Anderson Cancer Center;   Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials